Title : Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy.

Pub. Date : 2018 Dec 14

PMID : 30647852






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy. ibrutinib AXL receptor tyrosine kinase Homo sapiens
2 Ibrutinib-exposed CLL B-cells were treated with increasing doses (0.01- 0.50muM) of a new formulation of high-affinity Axl inhibitor, TP-0903 (tartrate salt), for 24 hours and LD50 doses were determined. ibrutinib AXL receptor tyrosine kinase Homo sapiens
3 We detected sustained overexpression of Axl in CLL B-cells from CLL patients on ibrutinib treatment, suggests targeting Axl could be a promising strategy to overcome drug resistance and killing of CLL B-cells in these patients. ibrutinib AXL receptor tyrosine kinase Homo sapiens
4 We detected sustained overexpression of Axl in CLL B-cells from CLL patients on ibrutinib treatment, suggests targeting Axl could be a promising strategy to overcome drug resistance and killing of CLL B-cells in these patients. ibrutinib AXL receptor tyrosine kinase Homo sapiens